Skip to main content

Advertisement

SpringerLink
Log in

Weight gain secondary to the use of Janus kinase inhibitors

  • REVIEW
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Damsky W, King BA (2017) JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 76(4):736–744

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. RINVOQ: Highlights of Prescribing Information. 2022.

  3. A study of baricitinib (LY3009104) in participants with severe or very severe alopecia areata (BRAVE-AA1). ClinicalTrials.gov identifier: NCT03570749. 2022.

  4. A study of baricitinib (LY3009104) in adults with severe or very severe alopecia areata (BRAVE-AA2). ClinicalTrials.gov identifier: NCT03899259. 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03899259.

  5. Unpublished internal company data - Eli Lilly and Company. 2022.

  6. Mollé N, Krichevsky S, Kermani P, Silver RT, Ritchie E, Scandura JM (2020) Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. Blood 135(13):1062–1066

    PubMed  Google Scholar 

  7. Sapre M, Tremblay D, Wilck E, James A, Leiter A, Coltoff A et al (2019) Metabolic effects of JAK1/2 inhibition in patients with myeloproliferative neoplasms. Sci Rep 9(1):16609

    Article  PubMed  PubMed Central  Google Scholar 

  8. Coltoff A, Mesa R, Gotlib J, Shulman J, Rampal RK, Siwoski O et al (2020) Real-world outcomes of ruxolitinib treatment for polycythemia vera. Clin Lymphoma Myeloma Leuk 20(10):697-703.e1

    Article  PubMed  PubMed Central  Google Scholar 

  9. Alimam S, Claire H (2017) Experience with ruxolitinib in the treatment of polycythaemia vera. Ther Adv Hematol 8(4):139–151

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yang CC, Khanna T, Sallee B, Christiano AM, Bordone LA (2018) Tofacitinib for the treatment of lichen planopilaris: a case series. Dermatol Ther 31(6):e12656

    Article  PubMed  PubMed Central  Google Scholar 

  11. Novikova DS, Udachkina HV, Markelova EI, Kirillova IG, Misiyuk AS, Demidova NV et al (2019) Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib. Rheumatol Int 39(7):1181–1189

    Article  CAS  PubMed  Google Scholar 

  12. Liu LY, Strassner JP, Refat MA, Harris JE, King BA (2017) Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol 77(4):675–82.e1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Chikugo M, Sebe M, Tsutsumi R, Iuchi M, Kishi J, Kuroda M et al (2018) Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism. J Med Invest 65(34):166–170

    Article  PubMed  Google Scholar 

  14. Wollenhaupt J, Morel J, Daien C, Ruyssen-Witrand A, Lukas C, Richez C, Shapiro A, Chapman D, Cros M, Rivas J, Citera G (2020) Analysis of the impact of tofacitinib treatment on weight in patients with rheumatoid arthritis. Arthritis Rheumatol 72 (suppl 10). https://acrabstracts.org/abstract/analysis-of-the-impact-of-tofacitinibtreatment-on-weight-in-patients-with-rheumatoid-arthritis/. Accessed 22 Aug 2023

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY, 10461, USA

    Peter Yi Ch’en

  2. College of Osteopathic Medicine of the Pacific Northwest, Lebanon, OR, USA

    Justin Ng

  3. Frontier Dermatology, Mill Creek, WA, USA

    Eingun James Song

Authors
  1. Peter Yi Ch’en
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Justin Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eingun James Song
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

PC and JN wrote the main manuscript text. ES provided revisions, guidance, and expertise in the creation of this review.

Corresponding author

Correspondence to Peter Yi Ch’en.

Ethics declarations

Conflict of interest

The authors declare that they have no  conflict of interest.

IRB approval status

Exempt.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ch’en, P.Y., Ng, J. & Song, E.J. Weight gain secondary to the use of Janus kinase inhibitors. Arch Dermatol Res 315, 2773–2774 (2023). https://doi.org/10.1007/s00403-023-02710-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-023-02710-6

Keywords

Search

Navigation